Reelin protects against amyloid beta toxicity in vivo


LANE-DONOVAN C., Philips G. T., WASSER C. R., DURAKOGLUGIL M. S., MASIULIS I., UPADHAYA A., ...More

SCIENCE SIGNALING, vol.8, no.384, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8 Issue: 384
  • Publication Date: 2015
  • Doi Number: 10.1126/scisignal.aaa6674
  • Journal Name: SCIENCE SIGNALING
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Çukurova University Affiliated: No

Abstract

Alzheimer's disease (AD) is a currently incurable neurodegenerative disorder and is the most common form of dementia in people over the age of 65 years. The predominant genetic risk factor for AD is the epsilon 4 allele encoding apolipoprotein E (ApoE4). The secreted glycoprotein Reelin enhances synaptic plasticity by binding to the multifunctional ApoE receptors apolipoprotein E receptor 2 (Apoer2) and very low density lipoprotein receptor (Vldlr). We have previously shown that the presence of ApoE4 renders neurons unresponsive to Reelin by impairing the recycling of the receptors, thereby decreasing its protective effects against amyloid beta (A beta) oligomer-induced synaptic toxicity in vitro. We showed that when Reelin was knocked out in adult mice, these mice behaved normally without overt learning or memory deficits. However, they were strikingly sensitive to amyloid-induced synaptic suppression and had profound memory and learning disabilities with very low amounts of amyloid deposition. Our findings highlight the physiological importance of Reelin in protecting the brain against A beta-induced synaptic dysfunction and memory impairment.